Litcius/Paper detail

Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer

Theeranan Tangthong, Thananchai Piroonpan, Velaphi C. Thipe, Menka Khoobchandani, Kavita Katti, Kattesh V. Katti, Wanvimol Pasanphan

2021Nanotechnology Science and Applications34 citationsDOIOpen Access PDF

Abstract

INTRODUCTION: Functionalization of water-soluble chitosan (WSCS) nanocolloids with, gold nanoparticles (AuNPs), and LyslLys3 (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-bombesin 1-14 (DOTA-BBN) peptide affords an innovative pathway to produce prostate tumor cell-specific nanomedicine agents with potential applications in molecular imaging and therapy. METHODS: The preparation involves the production and full characterization of water-soluble chitosan (WSCS), via gamma (γ) rays (80 kGy) irradiation, followed by DOTA-BBN conjugation for subsequent use as an effective template toward the synthesis of tumor cell-specific AuNPs-WSCS-DOTA-BBN. RESULTS: The WSCS-DOTA-BBN polymeric nanoparticles (86 ± 2.03 nm) served multiple roles as reducing and stabilizing agents in the overall template synthesis of tumor cell-targeted AuNPs. The AuNPs capped with WSCS and WSCS-DOTA-BBN exhibited average Au-core diameter of 17 ± 8 nm and 20 ± 7 nm with hydrodynamic diameters of 56 ± 1 and 67± 2 nm, respectively. The AuNPs-WSCS-DOTA-BBN showed optimum in vitro stability in biologically relevant solutions. The targeted AuNPs showed selective affinity toward GRP receptors overexpressed in prostate cancer cells (PC-3 and LNCaP). DISCUSSION: AuNPs theragnostic nanoradiopharmaceutical for use in cancer diagnosis and therapy.

Topics & Concepts

LNCaPDOTANanomedicineColloidal goldCytotoxicityBombesinProstate cancerMaterials scienceChitosanNanocarriersChemistryNanotechnologyNanoparticleCancer researchIn vitroCancerReceptorBiochemistryMedicineChelationInternal medicineOrganic chemistryNeuropeptideNanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsNanoplatforms for cancer theranostics